Published in Vaccine Weekly, July 26th, 2000
In discussing the theory behind their in vivo study, S. Elmir and co-investigators at the Institute Gustave Roussy in Villejuif, France, said, "The lymphocyte activation gene-3 (LAG-3) product is a MHC (major histocompatibility complex) class II ligand that has been used in vivo to stimulate MHC II+ APCs (antigen-presenting cells) to increase tumor-specific immune responses."
To look at the effect of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly